A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ramesh Ramanathan, MD
ZielBio, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic - Phoenix
Phoenix, Arizona, United States
- Mayo Clinic Jacksonville
Jacksonville, Florida, United States
- Mayo Clinic - Rochester
Rochester, Minnesota, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
- Next Oncology
Austin, Texas, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Next Oncology
San Antonio, Texas, United States
- University of Virginia
Charlottesville, Virginia, United States
- Next Onoology
Fairfax, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Jan 2022
- Primary completion
- 30 Aug 2023
- Completion
- 30 Sept 2023
- Last update posted
- 29 Jan 2024
- Registered enrollment
- 35
- Registry id
- NCT05074472
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.